20:01 , Jun 20, 2019 |  BC Innovations  |  Translation in Brief

Turning Tregs against cancer

Researchers from Massachusetts General Hospital found that inhibiting a signalosome complex in Treg cells could convert the immunosuppressive cell type into inflammatory cells in tumors, a strategy that could both increase the efficacy of checkpoint...
19:11 , Jun 11, 2019 |  BC Innovations  |  Distillery Therapeutics

CARD11, MALT1 inhibition sensitizes melanoma, colorectal tumors to PD-1 inhibitors

DISEASE CATEGORY: Cancer INDICATION: Melanoma; colorectal cancer Mouse studies suggest inhibiting CARD11 or MALT1 could help sensitize melanoma and colorectal cancer to PD-1 inhibitors. In mouse models of melanoma and colon cancer, conditional knockout of...
08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: c-jun N-terminal kinase (JNK); caspase recruitment domain family member 11 (CARD11)

Cancer INDICATION: B cell lymphoma Mouse and patient sample studies suggest JNK inhibitors could help treat a subtype of diffuse large B-cell lymphoma (DLBCL). Gain-of-function mutations in CARD11 are associated with poor outcomes in the...
08:00 , Dec 8, 2014 |  BC Week In Review  |  Company News

NeoGenomics sales and marketing update

NeoGenomics launched new tests to detect mutations in the Bruton’s tyrosine kinase (BtK) and phospholipase C gamma 2 (phosphatidylinositol-specific; PLCG2 ) genes for predicting acquired resistance to BtK inhibitors and a lymphoma profiling test that...